Glucocorticoid-induced osteoporosis in inflammatory bowel disease.
Osteoporosis secondary to glucocorticoid use is a potentially preventable disorder. It is the role of the physician to establish and maintain disease remission, minimize the use of glucocorticoids, and initiate measures to prevent and treat bone loss. The essentials of management include lifestyle modifications, nutritional interventions, and pharmacologic therapies. Bisphosphonates should be used when indicated.
Lidofsky
Sheldon
S
Warren Alpert Medical School of Brown University, USA. Sheldon_Lidofsky@brown.edu
Smith
Jeanette
J
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D017610:Calcium Compounds / Q000627:therapeutic use; D019587:Dietary Supplements; D004164:Diphosphonates / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy*; D010024:Osteoporosis / Q000139:chemically induced* / Q000628:therapy; D014807:Vitamin D / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D017610:Calcium Compounds; D004164:Diphosphonates; D005938:Glucocorticoids; D014807:Vitamin D